Metabolite Ratio Analysis for Hydration-Independent Medication Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current urine testing protocols for monitoring prescription drug adherence are inadequate due to significant variability in metabolite concentrations caused by hydration levels, leading to inaccurate detection of proper vs. improper medication use.
Innovation Solution
A method using the ratio of test metabolites to reference metabolites, with dose-specific normal distribution curves and confidence intervals, and computer-assisted products for analyzing urine samples to quantify and detect metabolites, reducing variability and improving clinical accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Difficulty of detecting and measuring
If urine testing is used to monitor medication compliance, then detection capability is improved, but measurement precision deteriorates due to hydration-induced concentration variability
Solution Approach 1:
The patent transforms the single metabolite concentration parameter into a ratio parameter (metabolite/creatinine). This parameter transformation eliminates the confounding effect of urine dilution, as creatinine concentration varies inversely with dilution. The ratio remains stable regardless of hydration status, thereby resolving the measurement precision problem while preserving detection capability.
Solution Approach 2:
The patent introduces creatinine as an intermediary reference substance. Creatinine serves as a internal standard that reflects urine concentration effects. By comparing the target metabolite concentration to creatinine concentration, the method uses this intermediary to cancel out dilution variability, thus improving measurement precision without sacrificing detection sensitivity.
2Ease of operation
If simple presence/absence testing is used, then ease of operation is improved, but loss of information increases due to inability to detect improper use patterns
Solution Approach 1:
The patent adds a quantitative dimension to the traditional qualitative urine test. Instead of merely detecting presence/absence, the method measures the ratio of metabolite to creatinine concentrations. This dimensional transformation enables detection of improper use patterns (such as dose dumping or non-compliance) while maintaining operational simplicity through automated ratio calculation and comparison against established ranges.
Data Source
AI summary
The present invention provides methods for detecting and quantifying metabolites in a biological sample by measuring the concentration of a test metabolite in the sample and comparing that concentration against the concentration of the reference metabolite; enabling accurate metabolite concentration measurements to determine aberrant drug usage patterns. Also disclosed is an analytical testing device and related computer-assisted products for detecting and quantifying metabolites in a biological sample efficiently and accurately.